Welcome to our dedicated page for Entheon Biomedic news (Ticker: ENTBF), a resource for investors and traders seeking the latest updates and insights on Entheon Biomedic stock.
Entheon Biomedic (ENTBF) is a biotechnology innovator leveraging AI and genetic testing to advance addiction treatment research. This page serves as the definitive source for verified company news, offering investors and industry observers timely updates on scientific developments and strategic initiatives.
Access curated press releases, regulatory filings, and partnership announcements to stay informed about ENTBF's progress in merging biotech with digital health solutions. Key updates include research milestones, technology integrations, and clinical advancements focused on substance use disorders.
Regularly updated content covers essential categories: R&D breakthroughs, strategic collaborations, and regulatory developments. Our neutral reporting ensures compliance with financial content standards while maintaining accessibility for all knowledge levels.
Bookmark this page or check back frequently to monitor how ENTBF's unique approach to AI-enhanced diagnostics continues shaping the future of addiction treatment.
Entheon Biomedical Corp (CSE: ENBI) (OTCQB: ENTBF) has announced a change in its Board of Directors. Harrison Newlands has been appointed to the board effective April 3, 2025, while Andrew Hegle has resigned.
Newlands brings nearly a decade of experience in start-ups and capital markets. His notable achievements include co-founding Fire & Flower, a Canadian retail cannabis company, where he served as Director of Business Development. He also co-founded Hoshi International, a medicinal cannabis producer in Portugal, and Hypercharge Networks, Canada's first publicly traded EV charging company.
His career began as a Research Associate at MacNicol and Associates on Bay Street. He has also served as a strategic advisor for Taiga Motors, was formerly a partner at Rockbank Capital, and currently serves as a managing partner at North King Capital, where he advises public and private companies.
Entheon Biomedical Corp (OTCQB: ENTBF) has announced the issuance of stock options to company directors. The granted options allow for the purchase of up to 40,000 common shares at an exercise price of $0.145 per share. These options will remain exercisable for a two-year period from the grant date. The options are governed under the company's incentive stock option plan, which was previously approved by shareholders at the annual general meeting on December 16, 2024.
Entheon Biomedical Corp (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) has announced that Mentis AI (1000141080 Ontario ) has terminated the letter of intent (LOI) dated January 23, 2025. The LOI had outlined the terms for Entheon's proposed acquisition of all issued and outstanding common shares of Mentis AI. This termination follows the company's previous news release dated January 24, 2025.
Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) has announced a binding letter of intent to acquire Mentis AI, a private R&D company focused on AI technologies for mental health and loneliness solutions. The acquisition will provide Entheon with AI companions and coaching tools to enhance their existing HaluGen's Psychedelics and Lobo's Cannabis Genetic Test Kit services.
The transaction will be structured as a share exchange, with Mentis AI shareholders receiving 12.84296 Entheon shares for each Mentis AI share, totaling approximately 11 million Entheon shares. Post-transaction, Mentis AI shareholders will own about 44.25% of Entheon's outstanding shares. The deal must be completed by February 28, 2025, subject to due diligence, definitive agreement execution, and regulatory approvals.
FAQ
What is the current stock price of Entheon Biomedic (ENTBF)?
What is the market cap of Entheon Biomedic (ENTBF)?
